Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab

Background: Rituximab is commonly used for systemic lupus erythematosus (SLE) but secondary non-depletion and non-response (2NDNR) associated with anti-drug antibodies is a notable problem with repeat rituximab cycles. Other B cell-targeted therapies include other anti-CD20 monoclonal antibodies or...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassan, Sabih Ul, Md Yusof, Md Yuzaiful, Emery, Paul, Dass, Shouvik, Vital, Edward M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481350/
https://www.ncbi.nlm.nih.gov/pubmed/32984378
http://dx.doi.org/10.3389/fmed.2020.00498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481350/
https://www.ncbi.nlm.nih.gov/pubmed/32984378
http://dx.doi.org/10.3389/fmed.2020.00498

Ejemplares similares